ZA200305384B - Silenced anti-CD28 antibodies and use thereof. - Google Patents
Silenced anti-CD28 antibodies and use thereof. Download PDFInfo
- Publication number
- ZA200305384B ZA200305384B ZA200305384A ZA200305384A ZA200305384B ZA 200305384 B ZA200305384 B ZA 200305384B ZA 200305384 A ZA200305384 A ZA 200305384A ZA 200305384 A ZA200305384 A ZA 200305384A ZA 200305384 B ZA200305384 B ZA 200305384B
- Authority
- ZA
- South Africa
- Prior art keywords
- antibody
- seq
- cells
- composition
- substance
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 claims description 148
- 238000000034 method Methods 0.000 claims description 64
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 37
- 239000013604 expression vector Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- 108091033319 polynucleotide Proteins 0.000 claims description 17
- 102000040430 polynucleotide Human genes 0.000 claims description 17
- 239000002157 polynucleotide Substances 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 10
- 206010052779 Transplant rejections Diseases 0.000 claims description 9
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 8
- 239000003018 immunosuppressive agent Substances 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 7
- 230000001506 immunosuppresive effect Effects 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- 206010062016 Immunosuppression Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 2
- 230000001861 immunosuppressant effect Effects 0.000 claims 7
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 56
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 56
- 108090000623 proteins and genes Proteins 0.000 description 51
- 241000699666 Mus <mouse, genus> Species 0.000 description 47
- 230000027455 binding Effects 0.000 description 33
- 238000002474 experimental method Methods 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 108700024394 Exon Proteins 0.000 description 19
- 238000000684 flow cytometry Methods 0.000 description 17
- 238000002965 ELISA Methods 0.000 description 16
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 16
- 238000003752 polymerase chain reaction Methods 0.000 description 16
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 15
- 241000283707 Capra Species 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 210000004408 hybridoma Anatomy 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 241000699800 Cricetinae Species 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 230000002297 mitogenic effect Effects 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 241000283074 Equus asinus Species 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 238000002054 transplantation Methods 0.000 description 9
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 8
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 8
- 229940045513 CTLA4 antagonist Drugs 0.000 description 8
- 108020004635 Complementary DNA Proteins 0.000 description 8
- 241001529936 Murinae Species 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 238000003146 transient transfection Methods 0.000 description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 102000010910 CD28 Antigens Human genes 0.000 description 6
- 108010062433 CD28 Antigens Proteins 0.000 description 6
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000001052 transient effect Effects 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 108010087819 Fc receptors Proteins 0.000 description 5
- 102000009109 Fc receptors Human genes 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 201000000050 myeloid neoplasm Diseases 0.000 description 5
- 230000009871 nonspecific binding Effects 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000012679 serum free medium Substances 0.000 description 5
- 230000003393 splenic effect Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 4
- 241000699679 Cricetulus migratorius Species 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000003153 stable transfection Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 102100032937 CD40 ligand Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000005094 computer simulation Methods 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 101150106093 gpt gene Proteins 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 230000006058 immune tolerance Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000000263 nonmitogenic effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 description 3
- 235000011009 potassium phosphates Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 238000011735 C3H mouse Methods 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000003712 Complement factor B Human genes 0.000 description 2
- 108090000056 Complement factor B Proteins 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 241000699673 Mesocricetus auratus Species 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102000008212 P-Selectin Human genes 0.000 description 2
- 108010035766 P-Selectin Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108090000919 Pyroglutamyl-Peptidase I Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 description 2
- 102000001555 Sialic Acid Binding Ig-like Lectin 3 Human genes 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012997 ficoll-paque Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 239000011544 gradient gel Substances 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101000852101 Bombyx mori DNA topoisomerase 2 Proteins 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 102000004497 CCR2 Receptors Human genes 0.000 description 1
- 108010017312 CCR2 Receptors Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 108090000270 Ficain Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102100026973 Heat shock protein 75 kDa, mitochondrial Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 description 1
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 101710204707 Transforming growth factor-beta receptor-associated protein 1 Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 241000133063 Trixis Species 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 1
- 235000019836 ficin Nutrition 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- -1 glycine Chemical class 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 102000053391 human F Human genes 0.000 description 1
- 108700031895 human F Proteins 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940046781 other immunosuppressants in atc Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940072288 prograf Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Surgery (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
®
SILENCED ANTI-CD28 ANTIBODIES AND USE THEREOF
This invention relates to anti-CD28 antibodies defective of mitogenic activity and to uses thereof.
Backeround of the Invention
Immune reactions, particularly organ transplant rejections, are chiefly attributed to the activation of T- lymphocytes. This activation of T cells is induced by a signal from antigen-presenting cells (APC). The signal from the APC involves a first signal via the T-cell receptor (TCR) and a second signal (costimulatory signal) via costimulatory molecules. The first signal is from the major histocompatibility antigen (MHC) complex of peptides antigen where the APC is presents the T-cell antigen through the TCR. The second signal is mediated by several co-stimulatory molecules, examples of which include B7 (B7-1 (CD80) and B7-2 (CD86)) are known as ligands on the APC side and CD28, CTLA-4, etc. as receptors on the T-cell side. The ligand B7 is a glycoprotein belonging to the immunoglobulin super family and is expressed in B cells etc. which belong to the antigen-presenting cell group. Both CD28 and CTLA-4, which recognize B7 as the common ligand, are transmembrane glycoproteins belonging to the immunoglobulin super family. Thus, the activation of T cells is regulated by the concurrent transduction of the first signal via TCR and the second signal from, e.g., the B7 and
CD28/CTLA-4. The signal from B7-to CD28 is known to promote whereas the signal from B7 to CTLA-4 inhibits the activation of T cells [Waterhouse et al., Science, 270:985-988 (1995)].
Heretofore, for the purpose of inducing immunosuppression or tolerance, attempts have been made to block the B7-CD28 signal by administering CTLA-4Ig, anti-B7-1 antibody/anti-B7-2 antibody, anti-CD28 antibody or the like. For example, CTIA-4Ig binds to B7 thereby interfering with the reaction between B7 and
CD28 and, as a consequence, block the signal from CD28 to exhibit immunosuppressive activity. However, since the reaction between B7 and CTLA-4 is also inhibited simultaneously, the signal of CTLA-4 acting negatively on the activation of T cells is also suppressed so that the desired tolerance is not induced (Kirk et al.
Proc. Natl. Acad. Sci. USA, 94:8789-8794 (1997). An anti-B7 antibody was also prepared and reported to have suppressed activation of T cells but just as in the case of CTLA-41g, it suppressed the CTLA-4 signal as well.
PCT/US01/47955 ® anti-CD28 antibody, in an in vitro experiment, was found to produce a mitogenic effect on T cells, and the combination of the stimulation with this antibody and an anti-CD3 antibody promoted the growth and activation of T cells and enhanced the production of cytokines [WO 90/05541, Eur. J. Immunology, 16, 1289-1296 (1986), etc.]. Furthermore, mitogenic stimulation of the CD28 receptor of the T cell by an anti-CD28 antibody has been stimulated in vivo resulted in the generation of a T-cell activation signal similar to the second signal from B7 to
CD28 [Yin et al., J. Immunology, 163:4328-4334 (1999)]. These T-cell activating functions suggested that an anti-CD28 antibody might be used as an immmunopotentiator in the therapy of cancer and AIDS (WO 90/05541).
The anti-CD28 antibodies prepared by conventional technologies exert a mitogenic action on T cells.
Although the reasons for this mitogenic activity is not fully understood, the binding of the anti-CD28 Fc region to the Fc receptor of the antigen-presenting cell is believed to be the probable reason (Cole et al., J.
Immunology, 36:159 (1997). Therefore, by utilizing genetic engineering technology, we introduced mutations into the Fc receptor binding site of the anti-CD28 antibody to modify the antibody so that it would no longer have mitogenic activity. One such antibody the present inventors have generated, TN228 IgG2M3, in which
IgG2M3 has two amino acid substitution in IgG gene. Furthermore, we demonstrated that the resulting silenced ’ anti-CD28 antibody has no mitogenic activity which is very useful for inducing T cell tolerance.
Therefore, the present invention provides anti-CD28 antibodies having no mitogenic activity ( hereinafter referred to as silenced anti-CD28 antibodies), and a methods of suppressing immune reactions, particularly transplant rejections, and inducing immunotolerance by using said antibodies.
An object of the present invention 1s a silenced anti-CD28 antibody, where the anti-CD28 antibody may be a chimeric antibody and/or a humanized antibody. The variable regions of the anti-CD28 antibodies may include the amino acid sequences shown in SEQID NOS: 2, 4,7 and 9 and polynucleotides encoding such . amino acid sequences. For example, such polnucleotides include SEQ ID NOS: 1, 3, 5, 6, and 8. :
Another object of the present invention is vectors and cell hosts comprising the polynucleotides which encode the anti-CD28 antibodies.
Another object of the present invention is methods for producing the silenced anti-CD28 antibody by culturing a cell host comprising the polynucleotides which encode the anti-CD28 antibodies under conditions which allow expression of the polynucleotide and collecting the gene products produced.
AMENDED SHEET
2 : c
®
Another object of the present invention is a pharmaceutical composition comprising one or more of the silenced anti-CD28 antibodies, preferably admixed with one or more pharmaceutically acceptable ingredients.
The silenced anti-CD28 antibodies are useful for inducing T-cell tolerance, immunosuppression and as a prophylactic/therapeutic drug for organ or tissue transplant rejection. Accordingly, the present invention provides methods for inducing T-cell tolerance, immunosuppression, and providing a prophylaxis or treatment therapy during an organ or tissue transplant rejection by administering one or more of the silenced anti-CD28 antibodies to a mammal. Preferably, such silenced anti-CD28 antibodies are administered in as a pharmaceutical composition as described herein and may include additional drug/pharmaceuticals where appropriate.
Figure 1. Plasmid constructs for C'TN228 antibody expression. VL and VH of murine TN228 were constructed as mini-exons flanked by Xbal sites. The VL sequence was incorporated into the expression vector pVk and the VH sequence was incorporated into the expression vector pVg2M3.
Figure 2. Nucleotide sequences and deduced amino acid sequences of the light chain of ChTN228 in the mini-exons. The signal peptide sequences are in italics. The CDRs are underlined. The mature light chain begins with an aspartic acid residue (bold letter). Untranslated and intron sequences are in lower case . (SEQ ID
NOS: 1 and 2).
Figure 3. Nucleotide sequences and deduced amino acid sequences of the heavy chain variable regions of ChTN228 in the mini-exons. The signal peptide sequences are in italics. The CDRs are underlined. The mature heavy chain begins with a glutamine residue (bold letter). Untranslated and intron sequences are in lower case. (SEQ ID NOS: 3 and 4).
Figure 4. Competition experiment. P81 5/CD28" cells were incubated with 25 ng of
MuTN228-FITC and two-fold serial dilutions of either ChTN228 or MuTN228 as described. P815/CD28' cells were also incubated with MuTN228-FITC alone, without any competitor. The mean channel fluorescence for each sample was plotted against the concentration of competitor.
Figure 5. Inhibition effect of TN228-IgG2m3 on human primary MLR(]). Percentage inhibition of primary MLR from four individuals were shown separately.
Figure 6. Inhibition effect of TN228-IgG2m3 on human primary MLR(2). Percentage inhibition of primary MLR from four individuals were shown separately.
~ PCT/US01/47955 ® Figure 7. The effect of TN228-IgG2m3 on secondary MLR.
The data from two volunteers were shown separately. [*H]-thymidine uptake in 2nd MLR were presented as percentage of dpm of Raji stimulation alone in
Ist MLR as 100. TN228-IgG2m3:0.lug/mL
Figure 8. Plasmid constructs for HuTN228 antibody expression. ‘VL and VH of humanized TN228 were constructed as mini-exons flanked by Xbal sites. The VL sequence was incorporated into the expression vector pVk and the VH sequence was incorporated into the expression vector pVg2M3 : : Figure 9. Nucleotide sequences and deduced amino acid sequences of the heavy chain variable regions of HUTN228 in the mini exons. The signal peptide sequences are in italics. The CDRs are underlined. The mature heavy chain begins with a glutamine residue (bold letter). (SEQ ID NOS: 6 and 7
Figure 10. Nucleotide sequences and deduced amino acid sequences of the light chain variable regions of HuTN?228 in the mini exons. The signal peptide sequences are in italics. The CDRs are underlined. The mature light chain begins with an aspartic acid residue (bold letter). (SEQ ID NOS:'8 and 9) -
Figure 11. FACS competition assay. The binding of FITC-labeled MuTN228 to P815/CD28' cells in the presence of various amounts of competitor MuTN228 or HuTN228 antibody was analyzed in a flow cytometry competition experiment as described in the examples.
Figure 12. ELISA competition assay. The binding of biotinylated MuTN228 to sCD28-Fc in the presence of various amounts of competitor MuTN228 or HuTN228 antibody was analyzed in an ELISA competition experiment as described in the examples. }
Figure 13. 1-125 competition assay. The binding of '*’I labeled MuTN228 to P815/CD28" cells in the presence of various amounts of competitor MuTN228 or HuTN228 antibody was analyzed in an '*I labeled antibody competition experiment as described in the examples.
Figure 14. Plasmid constructs for PV1-IgG3 antibody expression. V| and Vy of PV1 were constructed as mini-exons flanked by Xbal sites. The Vy sequence was incorporated into the expression vector pMVk.rg.dE, and the Vy sequence into the expression vector pMVg3.D. Tt. The two plasmids were then recombined to generate a single plasmid co-expressing the heavy and light chains of PV1-IgG3.
Figure 15A . Sequences of cDNA and deduced amino acid sequences of the light chain and heavy chain in the mini-exons. The CDRs are underlined. The mature light chain begins with an aspartic acid residue (double underlined) at position 20. (SEQ ID NOS:10 and 11). . : AMENDED SHEET
PCT/US01/47955 ® Figure 15B. Sequences of cDNA and deduced amino acid sequences of variable regions of PV1 in the mini-exons. The CDRs are underlined. The mature heavy chain with glutamine (double underlined) at position 20. (SEQ ID NOS: 12 and 13).
Figure 16. Analysis of PV-1-IgG3 by size exclusion chromatography using HPLC as described in
Methods. The protein was monitored by its absorbance at 280 nM.
Figure 17. SDS-PAGE analysis of mouse IgG3 isotype control (lane 1), PV1 (lane 2), and PV1-IgG3 (lane 3). Proteins in Panel A were run under nonreducing conditions, and in Panel B reducing conditions. MW . represents molecular weight markers. The numbers are MW standards in kD.
Figure 18. EL4 cells stained with PV1 (A), 37.51 (B), or PV1-1gG3 (C), and analyzed by flow cytometry.
Secondary antibodies used were: FITC-conjugated donkey anti-Armenian hamster IgG (H+L) for PV'1, FITC- conjugated donkey anti-Syrian hamster IgG for 37.51, and FITC-conjugated goat anti-mouse kappa for PV1-IgG3.
The solid line profiles represent cells stained with secondary antibodies only. The broken line profiles represent cells stained with both primary and secondary antibodies as described in Methods . Mouse IgG3 isotype control did not stain EL4 cells (data not shown).
Figure 19. (A). Excess PV1, or PVI-IgG3 competes with R-PE-conjugated PV1 for binding to
EL4 cells. Thin solid line (black) in flow cytometry histogram represents cells without any staining, thick solid line (dark blue) cells stained with R-PE-PV1 alone, thin broken line (magenta) cells stained with R-PE-PV1 and excess unconjugated PV1, and thin double broken line (light blue) cells stained with R-PE-PV1 and excess unconjugated PV1-IgG3. Excess mouse IgG3 isotype control had no effect on R-PE-PV1’s binding to EL4 cells (data not shown). (B). Excess 145.2C11, or 145.2C11-IgG3 compete with R-PE-conjugated 145.2C11 for binding to EL4. Thin solid line (black) represents cells without any staining, thick solid line (dark blue) cells stained with R-PE-145.2C11 alone, thin broken line (magenta) cells stained with R-PE-145.2C11 and excess "unconjugated 145.2C11, and thin double broken line (light blue) cells stained with R-PE-145.2C11 and excess unconjugated 145.2C1 1-IgG3. (C). Excess PV1 competes with PV1-I1gG3 for binding to EL4 cells. EL4 cells ’ 25 were stained with PV1-1gG3 with or without excess PV1. Cells were washed and stained with mouse IgG3- "specific, FITC-conjugated donkey anti-mouse IgG (H+L). Thin solid line (black) represents cells stained with secondary antibodies only, thick solid line (dark blue) cells stained with PV1-IgG3 and secondary antibodies, and thin broken line (magenta) cells stained with PV1-IgG3 and excess PV1, and secondary antibodies.
Figure 20. Mouse splenic cells stained with PV1-IgG3 and 145.2C11. Cells were stained with mouse
IgG3 isotype control (A) or PV1-IgG3 (B), counter-stained with R-PE-conjugated goat anti-mouse IgG3 and
AMENDED SHEET
® with FITC-conjugated 145.2C11, and analyzed by two-color flow cytometry as described in Materials and
Methods . Only cells in the lymphocyte gate were analyzed. PV1-1gG3-positive cells are in the upper quadrants and CD3-positive cells are in the right side quadrants. The number in each quadrant represents percentage of the cells in that particular quadrant. a
In the context of this invention, the term "silenced anti-CD28 antibody" means any anti-CD28 antibody defective of mitogenic activity. More specifically, it is an antibody which binds specifically to the antigen
CD28 receptor on the surface of the T cell and does not promote the growth or activation of T cells by combined stimulation with an anti-CD3 antibody.
A silenced anti-CD28 antibody can be constructed on the basis of an anti-CD28 antibody or an anti-
CD28 antibody-producing hybridoma by mutating or modifying an agonistic anti-CD28 antibody by a genetic engineering technique or by chemical modification. Taking the use of genetic engineering technology as an example, the binding affinity of the anti-CD28 antibody for the Fc receptors can be reduced or eliminated by introducing a mutation into the amino acid sequence of the Fc domain of the antibody. For example, a silenced anti-CD28 antibody can be obtained by isolating cDNA from hybridoma cells capable of producing an anti-
CD28 monoclonal antibody and introducing a mutation(s) into the region of the sequence corresponding to the
Fc domain which plays an important role in the binding to the Fc receptor (WO 88/07089). The site of mutation is not particularly restricted inasmuch as the binding to the Fc receptors may be inhibited. Thus, in the case ofa
Class IgG antibody, for instance, the H-chain amino acid residues 234, 235, 236, 237, 318, 320 and 322 are preferred and a silenced anti-CD28 antibody can be constructed by replacing at least one of these amino acids with a different amino acid.
The source of such a silenced anti-CD28 antibody can be judiciously selected according to the target animal in which the antibody is used. For example, nonhuman monoclonal antibodies contain amino acid sequences showing antigenicity in humans over a fairly broad range. Many studies have shown that the immune response of a patient to a foreign antibody following injection of the antibody is remarkably intense and the very administration of the antibody may bring the patient into a perilous condition or deprive the antibody of the therapeutic utility. Therefore, it is recommendable to replace the Fc region so as to make the antibody relatively more homologous to the therapeutic target animal, replace the framework potions of the variable regions, or use the antibody obtained from a transgenic animal into which the antibody gene of the target animal has been
"PCT/US01/47955 ® For example, when the antibody is to be administered to a human, a chimeric antibody (EP125023) available on replacement of the Fc region, a humanized antibody with the framework portion replaced (EP0239400, EP045126) or a human antibody (EP546073, WO 97/07671) obtained from a transgenic animal into which the human antibody gene has been introduced. By introducing mutations in these antibodies by . 5 genetic engineering techniques such as those described above or by chemical modification, the mitogenic activity of the antibodies can be reduced or eliminated.
As specific examples of the anti-CD28 antibody having a silenced Fc region, there can be mentioned not only the antibodies described hereinafter in the Examples section but also the antibodies synthetically prepared using the constant region gene of the therapeutic target animal and the variable region polynucleotides based on the amino acid sequences of variable regions shown in SEQ ID NO:2 and NO:4 or SEQ ID NO:7 and
NO:9. [Examples of such polynucleotides are SEQ ID NOS:1, 3, 6, and 8. . More specific examples of this invention are HuTN228 and MuTN228 and Fab fragments thereof
F(ab)’2 fragments thereof, derivatives thereof and etc..
As appreciated by those skilled in the art, because of third base degeneracy, almost every amino acid can be represented by more than one triplet codon in a coding nucleotide sequence. Further, minor base pair changes may result in variation (conservative substitution) in the amino acid sequence encoded, are not expected to substantially alter the biological activity of the gene product. Thus, a nucleic acid sequencing encoding a protein or peptide as disclosed herein, may be modified slightly in sequence (e.g., substitution of a nucleotide in a triplet codon), and yet still encode its respective gene product of the same amino acid sequence.
The term "expression vector" refers to an polynucleotide which encodes the peptide of the invention and provides the sequences necessary for its expression in the selected host cell. Expression vectors will generally include a transcriptional promoter and terminator, or will provide for incorporation adjacent to an endogenous promoter. Expression vectors will usually be plasmids, further comprising an origin of replication and one or more selectable markers. However, expression vectors may alternatively be viral recombinants designed to infect the host, or integrating vectors designed to integrate at a preferred site within the host's genome. Examples of expression vectors are disclosed in Molecular Cloning: A Laboratory Manual, Second
Edition, Sambrook, Fritsch, and Maniatis, Cold Spring Harbor Laboratory Press, 1989.
Suitable host cells for expression of the silenced anti-CD28 antibody include prokaryotes, yeast, archae, and other eukaryotic cells. Appropriate cloning and expression vectors for use with bacterial, fungal, | yeast, and mammalian cellular hosts are well known in the art, e.g., Pouwels ef al. Cloning Vectors: A
AMENDED SHEET
®
Laboratory Manual, Elsevier, New York (1985). Preferably, the cells are mammalian cells. The vector may be a plasmid vector, a single or double-stranded phage vector, or a single or double-stranded RNA or DNA viral vector. Such vectors may be introduced into cells as pelynucleotides, preferably DNA, by well known techniques for introducing DNA and RNA into cells. The vectors, in the case of phage and viral vectors also may be and preferably are introduced into cells as packaged or encapsulated virus by well known techniques for infection and transduction. Viral vectors may be replication competent or replication defective. In the latter case viral propagation generally will occur only in complementing host cells. Cell-free translation systems could also be employed to produce the proteins using RNAs derived from the present DNA constructs.
The silenced anti-CD28 antibodys/proteins can be purified by isolation/purification methods for proteins generally known in the field of protein chemistry. More particularly, there can be mentioned, for example, extraction, recrystallization, salting out with ammonium sulfate, sodium sulfate, etc., centrifugation, dialysis, ultrafiltration, adsorption chromatography, ion exchange chromatography, hydrophobic chromatography, normal phase chromatography, reversed-phase chromatography, gel filtration method, get permeation chromatography, affinity chromatography, electrophoresis, countercurrent distribution, etc. and combinations of these.
According to the present invention, purified antibodies may be produced by the recombinant expression systems described above. The method comprises culturing a host cell transformed with an expression vector comprising a DNA sequence that encodes the protein under conditions sufficient to promote expression of the protein. The protein is then recovered from culture medium or cell extracts, depending upon the expression system employed. As is known to the skilled artisan, procedures for purifying a recombinant protein will vary according to such factors as the type of host cells employed and whether or not the recombinant protein is secreted into the culture medium. : The silenced anti-CD28 antibody when formulated into a pharmaceutical composition can be used in (2) transplant rejections following the transplantation of organs or tissues, such as heart, kidney, liver, bone marrow, skin, cornea, lung, pancreas, small intestine, muscle, nerve, etc.; (b) graft-versus-host reactions in the transplantation of bone marrow; (c) autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, type I diabetes, etc.; and (d) immune diseases such as asthma, atopic dermatitis, etc.
While the silenced anti-CD28 antibody by itself can be expected to suppress immune reactions and transplant rejections and induce immunotolerance, it can also be used in combination with other drugs. Among
® such other drugs which are useful for combining with the silence anti-CD28 antibody are various immunosuppressants such as rapamycin, deoxyspergaulin, anti-CD40 antibody, anti-CD40L antibody, prograf, cyclosporin A, anti-IL-2 antibody, antiIL-2 receptor antibody, anti-IL-12 antibody, anti-IL12 receptor antibody and MMF. Rapamycin, in particular, inhibits transduction of the signal related to growth of T cells among signals from the IL2 receptor but does not inhibit transduction of the apoptosis-related signal, so that its use in combination with a specific inhibitor of the CD28 signal is expected to be useful.
The silenced anti-CD28 antibody of this invention can be administered orally or parenterally, preferably by the intravenous, intramuscular or subcutaneous route.
The silenced anti-CD28 antibody of this invention can be prepared in the form of a solution or a . lyophilized powder and, where necessary, may be formulated with various pharmaceutically acceptable additives such as an excipient, diluent, stabilizer, isotonizing agent and buffer. The preferred additives include a sugar such as maltose, a surfactant such as polysorbate, an amino acid such as glycine, a protein such as human serum albumin, and a salt such as sodium chleride.
Also, the dosage form such as injectable preparations (solutions, suspensions, emulsions, solids to be dissolved when used, etc.), tablets, capsules, granules, powders, liquids, liposome inclusions, ointments, gels, external powders, sprays, inhalating powders, eye drops, eye ointments, suppositories, pessaries, and the like can be selected appropriately depending on the administration method, and the peptide of the present invention can be accordingly formulated. Formulation in general is described in Chapter 25.2 of Comprehensive
Medicinal Chemistry, Volume 5, Editor Hansch et al, Pergamon Press 1990.
The dosage of the pharmaceutical composition of this invention is dependent on the specific composition, the type of disease as the target of therapy or prophylaxis, the method of administration, the patient's age and condition and the duration of treatment, among other variables. However, in the case of © intravenous, intramuscular or subcutaneous administration, 0.01-100 mg/kg, preferably 0.1-10 mg/kg, per day per adult can be administered.
When the silenced anti-CD28 antibody of this invention is used for suppression of transplant rejection or induction of immunotolerance in an organ or tissue transplantation, the composition can be administered in a dose of about 1 mg/kg/day immediately before transplantation, immediately after transplantation, and 3, 7, 12, 18, 25, 35, 45 and 60 days after transplantation, by intravenous, intramuscular or subcutaneous injection. The administration frequency and dosage may be judiciously increased or decreased while the course of rejection reaction after transplantation is monitored.
®
While the administration interval depends on the method of administration used and the patient's condition, among other factors, not only continuous administration but also intermittent administration is feasible. Thus, since the silenced anti-CD28 antibody of this invention is an antibody, it provides a sustained effect so that intermittent dosing may be rewarded with the expected efficacy. As to the period of treatment, once a tolerant state is established, this tolerance can be maintained even if the use of the silenced anti-CD28 antibody is discontinued. In this respect, this silenced anti-CD28 antibody is undoubtedly superior to other immunosuppressants the immunosuppressive effect of which declines after discontinuation.
Having generally described this invention, a further understanding can be obtained by reference to certain specific examples which are provided herein for purposes of illustration only, and are not intended to be limiting unless otherwise specified. The examples below are carried out using standard techniques, that are well known and routine to those of skill in the art, except where otherwise described in detail.
Example 1. Amino acid sequencing of the mouse anti-human CD28 antibody
The hybridoma producing anti-human CD28 antibody (clone: TN228, mouse IgGl kappa) was generously provided by Dr. Yagita (Juntendo University School of Medicine, Japan). Approximately 0.2 mg of purified anti-human CD28 antibody (TN228) was reduced in 0.64 M guanidine-HCI, 0.28 M Tris-HCI, pH 8.5, 0.055 M DT7 for 90' at 60 C (under argon), carboxymethylated by addition of iodoacetic acid to 0.13 M for 45' at room temperature (in the dark), followed by addition of DTr to 0.32 M (to terminate the carboxymethylation reaction), and immediately buffer-exchanged in 0.1 M sodium phosphate, 0.002 M EDTA, pH 8.0 using a PD- 10 column (catalog #17-0851-01, Amersham Pharmacia Biotech, Uppsala, Sweden). The eluate was adjusted to - 0.005 M DTT, 0.02 % glycerol, and one third of the solution (about 0.35 ml) was transferred to a separate tube for N-terminal deblocking of the heavy chain. The sample was digested with 1800 puU of pyroglutamate aminopeptidase (catalog # 7334, Takara Shuzo Co., Ltd., Tokyo, Japan) for 24 hours at 45 C. The N-terminal sequences of the light and heavy chains from the deblocked sample were determined by 20 cycles of automated
Edman degradation and PTH analysis-on a Model 241 Protein Sequencer (Hewlett Packard, Palo Alto, CA).
The PTH derivatives were analyzed on a Hypersil ODS C18 column. The sequencer and HPLC were operated according to the manufacturer's instructions using reagents, solvents, and columns obtained from Hewlett
Packard.
"PCT/US01/47955 ® N-terminal sequencing results for TN228 deblocked with pyroglutamate aminopeptidase were as follows: residue amino residueno | amino residueno | amino residue amino
BA A
CF
A lia a
JA i
Example 2. Cloning of variable region cDNAs
The V region cDNAs for the light and heavy chains of TN228 were cloned from the hybridoma cells by an anchored polymerase chain reaction (PCR) method described by Co et al. (Co, M.S., N.M. Avadalovic, P.C.
Caron, M.V. Avadalovic, D.A. Scheinberg, and C. Queen. 1992. Chimeric and humanized antibodies with specificity for the CD33 antigen. J. Immunol. 148: 1149-1154.). Amplification was performed on cDNA using 3 primers that anneal respectively to the mouse kappa and gamma chain C regions, and a 5' primer that anneals to the added G-tail of the cDNA. For VL PCR, the 3' primer has the sequence (SEQ ID NO: 14) : 5' TATAGAGCT! CAAGCTTGGATGGTGGGAAGATGGATACAGTTGGTGC 3 with residues 17- 46 hybridizing to the mouse Cy region. For VH PCR, the 3' primers have the degenerate . sequences (SEQ ID NOS: 15, 16 and 17):
A G T
5' TATAGAGCTCAAGCTTCCAGTGGATAGACCGATGGGGCTGTCGTTTTGGC 3' | ! with residues 17 - 50 hybridizing to mouse IgG Cyl. The non-hybridizing sequences in the two primer sets contain restriction sites used for cloning. The VL and VH cDNAs were subcloned into a TOPOII Blunt vector (Invitrogen, Inc., Carlsbad, CA) for sequence determination.
Several light and heavy chain clones were sequenced from two independent PCR reactions. For the light chain, two unique sequences homologous to mouse light chain variable regions were identified. One VL
AMENDED SHEET
® sequence was non-functional due to a frame shift mutation and was identified as the non-productive allele. The other VL sequence was typical of a functional mouse kappa chain variable region. For the heavy chain, a unique sequence homologous to a typical mouse heavy-chain variable region was identified. Their nucleotide sequences and their deduced amino acid sequences of variable region are described in Fig. 2 and Fig. 3. (Methods)
TN228 V, and V}; were converted by PCR into mini-exon segments flanked by Xbal sites as described by He et al. (He, X.Y., Z. Xu, J. Melrose, A. Mullowney, M. Vasquez, C. Queen, V. Vexler, C. Klingbeil, M.S.
Co, and E.L. Berg. 1998. Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P-selectin. J. Immunol. 160; 1029-1035) and were subcloned into the light chain and heavy chain expression plasmids (Fig. 1). Each mini-exon contains a signal peptide sequence, a mature variable region sequence and a splicing donor sequence derived from the most homologous mouse J chain gene. Such splicing donor sequences are used to splice the V region exon to the human antibody constant region. Each mini-exon was sequenced after it had been cloned into the expression vector to ensure the correct sequence was obtained and that no PCR errors were generated. The constant region exons of the light and heavy chain expression plasmids were also confirmed by sequencing.
In this specification, ChTN228 refers to a chimeric antibody containing the mouse TN228 VL and VH variable regions, a human IgG2M3 constant region for the heavy chain, and a human kappa constant region for the light chain. The heavy chain constant region was modified (Cole, M.S., C. Anasetti, and J.Y. Tso. 1997.
Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells. J. Immunol. 159: 3613-3621) from the germline human 2 genomic fragment, and the light chain was derived from the germline human K genomic - fragment. Both the heavy and light chain genes are driven by the human cytomegalovirus major immediate early promoter and enhancer. The heavy chain gene is followed by the transcription terminator derived from the human complement gene C2 (Ashfield, R., P. Enriquez-Harris, and N.J. Proudfoot. 1991. Transcriptional termination between the closely linked human complement genes C2 and factor B: common termination factor for C2 and c-myc? EMBO J. 10: 4197-4207). The light chain selection marker gpt gene (Mulligan, R.C., and P.
Berg. 1981. Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase. Proc. Natl. Acad. Sci. USA 78: 2072-2076) and the heavy chain selection marker dhfr gene (Simonsen, C.C., and A.D. Levinson. 1983. Isolation and expression of an altered mouse
® dihydrofolate reductase cDNA. Proc. Natl. Acad. Sci. USA 80: 2495-2499) are both driven by the SV40 early promoter. For expression of chimeric TN228, transient transfection into COS-7 cells (monkey kidney cell line) was done using lipofectamine (catalog # 10964-013, GIBCO BRL). Spent media from transient transfectants were analyzed for human IgG2M3 antibody production by ELISA, using goat anti-human IgG gamma chain specific antibody as- capturing reagent and HRP-conjugated goat anti-human kappa chain antibody as developing reagent. The spent media was also tested for the ability of ChTN228 to bind to P815/CD28" cells (stably transfected cell with CD28 into P815 (mouse mastcytomna)) by indirect immunofluorescent staining and analyzed by flow cytometry. For stable cell line -production, the chimeric expression plasmids were transfected into murine myeloma cell line Sp2/0 by electroporation and the transfectants were selected for gp expression.
The spent media from stable transfectants were analyzed by ELISA as for the transient transfection.
Results
The cloned V, and Vy; genes were converted into mini-exons by PCR (Fig. 2 and 3) and subcloned into the light and heavy chain expression vectors as described above and shown in Fig. 1.
Transient transfection of COS-7 cells: The chimeric expression vectors were transiently transfected into monkey kidney cell line COS-7 to produce the chimeric TN228" antibody. Spent medium from the transfected cells was tested by ELISA for the production of chimeric IgG2M3 antibodies and by flow cytometry for binding to P815/CD28" cells. Spent medium was positive in both assays. The yield of chimeric antibody from transient transfection was ~0.9 pg/ml. The ChTN228 antibody from transient supernatant bound to P815/CD28" cells in a concentration dependent manner (data not shown).
Stable transfection of Sp2/0 cells: The chimeric expression vectors were transfected into Sp2/0 cells for the production of a stable cell line. Spent media from several transfectants were tested for the production of . chimeric TN228 antibody and for binding to P815/CD28" cells as with the transient transfectants. Most transfectants were positive for both assays. One transfectant was chosen for its higher antibody productivity and expanded to grow in 5 L of serum free medium. ChTN228 was purified from 5 L of spent medium by affinity chromatography. The yield of purified antibody was ~25 mg.
Example 4 Protein purification of chimeric antibody ChTN228
One of the high ChTN228§ expressing transfectants from the stable transfection (Clone 7H) was grown in 5 L of GIBCO hybridoma serum-free medium (catalog # 12045-076, GIBCO BRL). Spent culture
® supernatant was harvested when cell viability reached 10 % or below, concentrated to 500 ml, and loaded onto a ml protein-A Sepharose column using a Pharmacia P1 pump (2-3 ml/min). The column was washed with PBS before the antibody was eluted with 0.1 M Glycine, 0.1L M NaCl, pH 2.7. The eluted protein was dialyzed against 3 changes of 2 L PBS and then desalted onto a PD-10 column equilibrated with PBS containing an 5 additional 0.1 M NaCl. The desalted protein solution was filtered through a 0.2 um filter prior to storage at 4 C.
Example 5 Purity determination by size exclusion HPLC and SDS-PAGE
Size exclusion HPLC was performed using a Perkin Elmer HPLC system consisting of a PE ISS 200
Advanced LC Sample Processor, a PE Series 410 Bio LC Pump, a PE 235C Diode Array Detector, and a PE
Nelson 600 Series LINK. Perkin Elmer Turbochrom Navigator Version 4.1 software was used to control the autosampler, pump, and detector, and to acquire, store, and process the data. Separation was achieved using two
TosoHaas TSK-GEL G3000SWXL size exclusion HPLC columns, 7.8 mm x 300 mm, 5 pm particle size, 250 A pore size (catalog # 08541, TosoHaas, Montgomeryville, MD) connected in series. The mobile phase was 200 mM potassium phosphate/150 mM potassium chloride at pH 6.9, and the flow rate was 1.00 mL/minute. The column eluate was monitored spectrophotometrically at both 220 mn and 280 nm. The injection volume was 50 pL (50 pg) of the ChTN228 sample.
SDS-PAGE was performed according to standard procedures on a 4-20% gradient gel (catalog #
EC6025, Novex, San Diego, CA).
The purity of the isolated ChTN228 was analyzed by size exclusion HPLC and SDS-PAGE. Based on this analysis, the protein is 96.5 % monomer and has the mobility corresponding to a protein of molecular weight ~160 kD. SDS-PAGE analysis of MuTN228, isotype control MuFd79 (mouse IgGl), ChTN228, and isotype control HUuEP5C7 (human IgG2M3) under nonreducing conditions also indicated that all four antibodies - have a molecular weight of about 150-160 kD. Analysis of the same four proteins under reducing conditions indicated all four antibodies were comprised of a heavy chain with a molecular weight of about 50 kD and a light chain with a molecular weight of about 25 kD.
Example 6. Competition experiment: °
Methods
A titration experiment was done using serial two-fold dilutions of MuTN228-FITC antibody beginning at 250 ng/est. P815/CD28" cells (5x10° cells/test) were incubated with FITC-labeled antibody for 1 hour on ice,
® washed with PBS and analyzed by flow cytometry. For the competition experiments, 25 ng of MuTN228-FITC and serial two-fold dilutions of competing ChTN228 or MuTN228 antibodies beginning at 800 ng/test were added to P815/CD28" cells (5x 10° cells/test). As a control, P815/CD28" cells (5x10° cells/test) were incubated with 25 ng of MuTN228-FITC alone (i.e. without any competitor). HuEP5C7 and MuFd79 isotype control antibodies (800ng/test) were also tested as competitors. Cells were incubated with the antibody mixture in a final volume of 150 p1 for one hour on ice (in the dark), then washed and analyzed by flow cytometry.
Results
The binding specificity of the MuTN228 and ChTN228 antibodies was compared in a flow cytometry competition experiment as described in the Methods. Various amounts of unlabeled MuTN228 or ChTN228 were mixed with 25 ng of FITC-labeled MuTN228 antibody and incubated with P815/CD28' cells. Both
MuTN228 and ChTN228 competed with MuTN228-FITC in a concentration dependent manner, indicating that binding of both antibodies is specific for the CD28 antigen (Fig. 4). The isotype control antibodies MuFd79 and
HuEP5C7 did not compete with MuTN228-FITC, indicating that the MuTN228 and ChTN228 antibodies recognize the CD28 antigen through V-region specific interactions.
Example 7 Chimeric anti-human CD28 antibody which has reduced affinity to human F R inhibits primary mixed lymphocyte reaction.
Cell preparation
Human peripheral blood mononuclear cells (PBMC) were prepared from normal healthy volunteers by density gradient centrifugation using Ficoll-Paque plus (Amersham Pharmacia Biotech, Tokyo, Japan). Human blood were diluted with equal volume of RPMI1640 and overlaid on Ficoll-Paque plus. After centrifugation for . 30 min. at room temperature, PBMCs were collected and washed with RPM 11640. Thereafter, PBMCs were suspended with the medium(RPMI1640 containing 2.5% human type AB serum, 2-mercaptoethanol, and antibiotics) and applied to a nylon fiber column(Wako junyaku, Osaka, Japan). After 1 hr incubation at 37 C in 5% CO,, T cells were eluted with warm medium.
®
Human B cell lines (Raji and TY) were used as stimulator cells in the mixed lymphocyte reaction.
These cells were X-ray irradiated (2000R) before use.
Primary mixed lymphocyte reaction (1* MLR)
Purified human T cells (1 x 10° cells/well) and irradiated Raji (1 x 10° cells/well) were plated in 96well flat bottom micro plate. Antibodies were added to the culture medium and cells were incubated for 7 days. All cultures were labeled for final 6 hours with 10 kBg/well [*H]thymidine (Amersham Pharmacia biotech). Cells were harvested and incorporated radioactivity was measured by liquid scintillation counter.
The effect of TN228-IgG2m3 (ChTN228) on primary MLR was shown on Fig.5 and 6. The original anti-human CD28 antibody TN228 (MuTN228) did not inhibit primary MLR, however, chimeric antibody
TN228-IgG2m3 inhibited in a dose dependent manner. Therefore, conversion of Fc region of anti-human CD28 antibody to one with reduced affinity to human Fc R makes the antibody antagonistic to T cell proliferation.
Chimeric anti-human CD28 antibody which has reduced affinity to human Fc R reduced T cell low responsiveness in secondary mixed lymphocyte reaction.
Secondary mixed lymphocyte reaction (2 MLR)
Purified human T cells (1 x 10° cells/well) and irradiated Raji cells (1 x 10° cells/well) were plated in 96-well flat bottom micro plates. Antibodies were added to the culture medium and cells were incubated. After 5 days, cells were collected, washed with fresh medium. Cells were, suspended with fresh medium and cultured for 8 days. Cells were restimulated with irradiated Raji or JY cells. After additional 7 days culture, cells were incubated with 10 kBg/well [*H]thymidine for 6 hours. Cells were harvested and radioactivity was measured by liquid scintillation counter. : TN228-IgG2m3 inhibited primary MLR (Fig. 5 and 6). Next, we analyzed the effect of this antibody on secondary MLR. The antibody was applied to primary MLR culture, then antibody was removed from culture supernatant. After culturing in the medium without antibodies, cells were re-stimulated with the same stimulator cells(Raji) or third party stimulator(JY). The proliferation of cells treated with TN228-1gG2m3 through primary MLR was reduced compared to that of none-treated cells. However, both cells proliferated to almost the same extent with third party stimulator (JY) (Fig. 7). This result indicates that anti-human CD28 antibody with reduced affinity to human Fc R may induce T-cell energy through alo-antigen stimulation.
Example 8. Design of humanized TN228 variable regions
®
The V-region sequences of MuTN228 were analyzed by computer modeling. Based on a sequence homology search against the Kabat antibody sequence database (8. Johnson, G., and T.T. Wu. 2000. Kabat database and its applications: 30 years after the first variability plot. Nucleic Acids Res. 28: 214-218), IC4 (Manheimmer-Lory, A., J.B. Katz, M. Pillinger, C. Ghossein, A. Smith, B. Diamond. 1991. Molecular characteristics of antibodies bearing an anti-DNA-associated idiotype. J. Exp. Med. 174: 1639-1652) was selected to provide the framework for both the humanized TN228 heavy chain and light chain variable regions.
The humanized TN228 heavy chain variable domain has 65 residues out of 85 framework residues that are identical to those of the mouse TN228 heavy chain framework, or 76% sequence identity. The humanized
TN228 light chain variable domain has 56 residues out of 80 framework residues that are identical to those of the mouse TN228 light chain framework, or 70% sequence identity.
The computer programs ABMOD and ENCAD (Levitt, M. 1983. Molecular dynamics of native protein. I. Computer simulations of trajectories. J. Mol. Biol. 168: 595-620) were used to construct a molecular model of the TN228 variable domain, which was used to locate the amino acids in the mouse TN228 framework that are close enough to the CDRs to potentially interact with them. To design the humanized
TN228 heavy and light chain variable regions, the CDRs from the mouse TN228 heavy chain were grafted into the framework regions of the human IC4 heavy chain and the CDRs from the mouse TN228 light chain were grafted into the framework regions of the human IC4 light chain. At framework positions where the computer model suggested significant contact with the CDRS, the amino acids from the mouse antibody were substituted for the original human framework amino acids. For humanized TN228, this was done at residues 27, 29, 30, 48, 67, 71 and 78 of the heavy chain. For the light chain, no substitutions were made (i.e., a straight grafting of the
MuTN228 CDRs into the IC4 framework region was done). Furthermore, framework residues that occurred only rarely at their positions in the database of human antibodies were replaced by human consensus amino . acids at those positions. For humanized TN228 this was done at residues 23, 40, 73, 83 and 85 of the heavy chain and at residues 69 and 77 of the light chain. The amino acid sequences of the humanized
TN228 antibody heavy and light chain variable regions are shown Figure 9 and 10.
Example 9. Construction and expression of humanized TN228-1gG2M3
Methods
Once the humanized variable region amino acid sequences had been designed as described above, genes were constructed to encode them, including signal peptides, splice donor signals and appropriate
® restriction enzyme sites (Figure 8). The heavy and light chain variable region genes were constructed and amplified using eight overlapping synthetic oligonucleotides ranging in length from approximately 65 to 80 bases (He, X.Y, Z. Xu, J. Melrose, A. Mullowney, M. Vasquez, C. Queen, V. Vexler, C. Klingbeil, M.S. Co, and E.L. Berg. 1998. Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P-selectin. J. Jmmunol. 160: 1029-1035). The oligonucleotides were annealed pairwise and extended with the Klenow fragment of DNA polymerase I, yielding four double-stranded fragments. The resulting fragments were denatured, annealed pairwise, and extended with Klenow, yielding two fragments. These fragments were denatured, annealed pairwise, and extended once again, yielding a full-length gene. The resulting product was amplified by polymerase chain reaction (PCR) using Taq polymerase, gel-purified, digested with Xbal, gel- purified again, and subcloned into the Xbal site of pVg2M3 for the expression of heavy chain, and pVk for the expression of light chain. The pVg2M3 vector for human gamma 2 heavy chain expression (Cole, M.S, C.
Anasetti, and J.Y. Tso. 1997. Human'IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells. I.
Immunol. 159: 3613-3621), and the pVk vector for human kappa light chain expression (CO, M.S., N.M.
Avadalovic, P.C. Caron, M.V. Avadalovic, D.A. Scheinberg, and C. Queen. 1992. Chimeric and humanized antibodies with specificity for the CD33 antigen. J. Immunol. 148:1149-1154) have been previously described.
The sequences of the V-regions and constant region exons of the heavy and light chain final plasmids were verified by nucleotide sequencing. The gross structures of the final plasmids were verified by restriction mapping. All DNA manipulations were performed by standard methods.
In this specification, HuTN228 refers to a humanized antibody containing the humanized TN228 Vy, and V variable regions, a human IgG2M3 constant region for the heavy chain, and a human kappa constant region for the light chain. The heavy chain constant region was modified (Cole, M.S. C. Anasetti, and J.Y. Tso. 1997. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells. J. Immunol. 159: 3613-3621) . from the germline human 2 genomic fragment, and the light chain was derived from the germline human K genomic fragment. The human cytomegalovirus major immediate early promoter and enhancer drive both the heavy and light chain genes. The heavy chain gene is followed by the transcription terminator derived from the human complement gene C2 (Ashfield, R., P. Enriquez-Harris, and N.J. Proudfoot. 1991. Transcriptional termination between the closely linked human complement genes C2 and factor B: common termination factor for C2 and c-myc? EMBO J. 10: 4197-4207). The light chain selection marker gpt gene (Mulligan, R.C,, and P.
Berg. 1981. Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase. Proc. Natl. Acad. Sci. USA 78: 2072-2076) and the heavy chain selection marker
® dhfi gene (Simonsen, C.C., and A.D. Levinson. 1983. Isolation and expression of an altered mouse dihydrofolate reductase cDNA. Proc. Natl. Acad. Sci. USA 80: 2495-2499) are both driven by the SV40 early promoter. .
For expression of HuTN228, transient transfection into COS-7 cells (monkey kidney cell line) was done using Lipofectamine 2000 (catalog # 11668-027, Life Technologies). Spent media from transient transfectants were analyzed for human IgG2M3 antibody production by ELISA, using goat anti-human IgG gamma chain specific antibody as capturing reagent and HRP-conjugated goat anti-human kappa chain antibody as developing reagent. The spent media were also tested for the ability of HuTN228 to bind to P815/CD28" cells by indirect immunofluorescent staining and analyzed by flow cytometry (data not shown). For stable cell line production, the humanized expression plasmids were transfected into murine myeloma cell line Sp2/0 by electroporation and the transfectants were selected for gpt expression. The spent media from stable transfectants were analyzed by ELISA as for the transient transfection.
Results
Based on the humanized V-region amino acid sequence design, heavy and light chain V-genes (Figure 9 and 10) were constructed as described in the Methods. The heavy and light chain V-genes were cloned into the pVg2M3 and pVk vectors, respectively, as shown in Figure 8. Several clones were analyzed by nucleotide sequencing and correct clones of both the heavy chain and light chain expression vectors were used for the transfection. The constant regions of both the heavy and light chain expression vectors were also confirmed by sequencing.
Transient transfection of COS-7 cells: The expression vectors were transiently transfected into - monkey kidney cell line COS-7 to produce the HuTN228 antibody. Spent medium from the transfected cells was tested by ELISA for the production of humanized gG2M3 antibodies and by flow cytometry for binding to
P8IS/ CD28" cells (data not shown). Spent medium was positive in both assays. The yield of humanized antibody from transient transfection was -3.7 g/ml. The HuTN228 antibody from transient supernatant bound to
P815/CD28" cells in a concentration dependent manner (data not shown).
@® .
Stable transfection of Sp2/0 cells: The humanized expression vectors were transfected into Sp2/0 cells for the production of a stable cell line. Spent media from several transfectants were tested for the production of
HuTN228 antibody as with the transient transfectants. One transfectant (clone 4) was chosen for its higher antibody productivity and expanded in GIBCO hybridoma serum free medium. HuTN228 antibody was purified from 570 ml of spent medium by affinity chromatography. The yield of purified antibody was ~7 mg.
Example 11. Protein purification.
One of the high HuTN228 expressing transfectants from the stable transfection (Clone 4) was grown in 570 ml of GIBCO hybridoma serum-free medium (catalog # 12045076, Life Technologies). Spent culture supernatant was harvested when cell viability reached 10% or below and loaded onto a 2 ml protein-A
Sepharose column. The column was washed with PBS before the antibody was eluted with 0.1 M Glycine, 0.1
M NaCl, pH 2.5. The eluted protein was dialyzed against 3 changes of 2 L PBS and then desalted onto a PD-10 column equilibrated with PBS containing an additional 0.1 M NaCl. The desalted protein solution was filtered through a 0.2 m filter prior to storage at 40C.
Example 11. Purity determination by size exclusion HPLC and SDS-PAGE
Methods
Size exclusion HPLC was performed using a Perkin Elmer HPLC system consisting of a PE ISS 200
Advanced LC Sample Processor, a PE Series 410 Bio LC Pump, a PE 235C Diode Array Detector, and a PE
Nelson 600 Series LINK. Perkin Elmer Turbochrolm Navigator Version 4.1 software was used to control the autosampler, pump, and detector, and to acquire, store, and process the data. Separation was achieved using two
TosoHaas TSK-GEL G3000SWXL size exclusion HPLC columns (7.8 mm x 300 mm, 5 m particle size, 250 . pore size; catalog # 08541, TosoHaas, Montgomeryville, MD) connected in series. The mobile phase was 200 mM potassium phosphate/150 mM potassium chloride at pH 6.9, and the flow rate was 1.00 mL/minute. The column eluate was monitored spectrophotometrically at both 220 nm and 280 mn. The injection volume was 60 1(60 g) of the HUTN228 sample.
SDS-PAGE was performed according to standard procedures on a 4-20% gradient gel (catalog #
EC6025, Novex, San Diego, CA).
The isotype of the purified antibody was confirmed using the Human IgG Subclass Profile ELISA Kit (catalog # 99-1000, Zymed Laboratories, South San Francisco, CA) following the manufacturer's recommendations. (Results)
®
The purity of the isolated HuTN228 antibody was analyzed by size exclusion HPLC and SDS-PAGE.
The HPLC elution profile of HuTN228 is not shown. Based on this analysis, the protein is -98% monomer and has the mobility corresponding to a protein of molecular weight -160 kD.
SDS-PAGE analysis of MuTN228, isotype control MuFd79 (mouse IgGl), Hu'TN228, and isotype control HuEP5C7 (human IgG2M3) under nonreducing conditions also indicated that all four antibodies have 2 molecular weight of about 150-160 kD. Analysis of the same four proteins under reducing conditions indicated that all four antibodies were comprised of a heavy chain with a molecular weight of about 50 kD and a light chain with a molecular weight of about 25 kD.
The isotype test indicated that the isotype of the HuTN228 antibody was consistent with the expected
IgG2 isotype (data not shown).
Example 12. FACS competition experiment.
Methods
A titration experiment was done using serial two-fold dilutions of MuTN228-FITC antibody beginning at 250 ng/test. P815/CD28" cells (3x105 cells/test) were incubated with FITC-labeled antibody for 1 hour on ice in 100 1of FACS Staining Buffer (FSB = PBS, 2% FBS, 3% normal mouse serum, 0.1% NaN) washed with 2 ml of FSB, and analyzed by flow cytometry (data not shown).
For the competition experiments, MuTN228-FITC (50 ng/test) in 25 1 of FSB was combined with three-fold serial dilutions of competing HuTN228 or MuTN228 antibodies (beginning at 200 g/ml) in 25 1 of
FSB, and added to P815/CD28" cells (3x10° cells/test) in 50 1 of FSB. As a control, P815/CD28" cells were incubated with MuTN228-FITC alone (50 ng/test in 50 10of FSB). HuEP5C7 (human IgG2M3) and MuFd79 (mouse IgGl) isotype control antibodies (200 g/ml) in 25 1 of FSB were also tested as nonspecific competitors. . Cells were incubated with the antibody mixture in a final volume of 100 1 for one hour on ice (in the dark), then washed with 2 ml of FSB, and analyzed by flow cytometry. This experiment was repeated three times.
Results
The binding specificity of the MuTN228 and HuTN228 antibodies to CD28 molecules on P815/CD28§* cells was compared in a flow cytometry competition experiment as described in the Methods. A representative result is shown in Figure 5. Both MuTN228 and HuTN228 competed with MuTN228-FITC in a concentration dependent manner, indicating that binding of both antibodies is specific for the CD28 antigen. The relative binding of HuTN228 was a few fold less than that of MuTN228. The isotype control antibodies MuFd79 and
®
HuEP5C?7 did not compete with MuTN228-FITC, indicating that the MuTN228 and HuTN228 antibodies recognize the CD28 antigen through V-region specific interactions.
Example 13. ELISA competition experiment.
Methods
A 96 well ELISA plate (Nunc-Immuno plate, catalog # 439454, NalgeNunc, Naperville, IL) was coated with 100 Vwell of sCD28-Fc (0.5 g/ril in PBS) (sCD28-Fc means the fused protein, in which the extracellular domains of CD28 were combined with the CH2 and CH3 domains of IgGl.) overnight at 4 C. The plate was blocked for 30 minutes with 300 /well of Superblock Blocking Buffer in TBS (catalog # 37535, Pierce,
Rockford, IL), and washed with 300 Vwell of ELISA Wash Buffer (EWB = PBS, 0.1% Tween-20). A mixture of MuTN228-biotin (0.5 g/ml) in 100 1 of ELISA Buffer (EB = PBS, 1% BSA, 0.1% Tween-20) and three-fold serially diluted HuTN228 or MuTN228 competitor antibodies (starting at 100 g/ml) in 100 1 of EB was added in triplicate in a final volume of 200 well. Isotype control antibodies HUEP5C7 and MuFd79 (100 g/ml) in 100 1of EB were also tested as non-specific competitors. As a 'no competitor’ control, 100 1 of EB was added to 100 1 of MuTN228-biotin (0.5 g/ml). As a blank, 200 | of EB was added to the remaining wells (containing no MuTN228-biotin). The plate was incubated at room temperature for 1.5 hours with shaking. After washing the wells 4 times with 300 Vwell of EWB, 100 l/well of Streptavidin-HRP (1 g/ml, catalog # 21124, Pierce) was added to all the wells. The plate was incubated at room temperature for 1 hour with shaking. After washing the wells as above, 100 /well of ABTS substrate (catalog #507602 & 506502, KPL, Gaithersburg,
MD) was added to all the wells. Tlie plate was incubated at room temperature for 5-7 minutes and the optical density was read at 415 nm. This experiment was repeated three times. "Results
The binding specificity of the HUTN228 and MuTN228 antibodies to sCD28-Fc was compared in an
ELISA competition experiment as described in the Methods. A representative result is shown in Figure 12,
Both MuTN228 and HuTN228 compéted with MuTN228-biotin in a concentration dependent manner. The isotype control antibodies MuFd79 and HuEP5C?7 did not compete with MuTN228-biotin, indicating that the
MuTN228 and HuTN228 antibodies recognize the CD28 antigen through V-region specific interactions. The
ICs, values of MuTN228 and HuTN228 for all three experiments are shown in Table 2. The relative binding of
HuTN228 was on average 2.6 fold less than that of MuTN228.
®
Table 2. ELISA competition summary
ICs ( g/ml)
Example 14. 151 labeled antibody competition experiment
Methods
The relative binding affinities of the MuTN228 and HuTN228 antibodies were determined following the method of Queen et al. (Queen, C., W.P. Schneider, H.E. Selick, P.W. Payne, N.F. Landolfi, .F. Duncan,
N.M. Avdalovic, M. Levitt, R.P. Junghans, T.A. Waldmann. 1989. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. 86:10029-10033). Briefly, ~10 ng of 125]_labeled MuTN228 in 50 1 of Binding Buffer (BB = PBS, 2% FBS, 1 g/ml mouse IgG, 0.1% Nal,) was combined in triplicate with three- fold serial dilutions of MuTN228 or HuTN228 competitor antibodies (beginning at 400 g /ml) in 50 1 of BB, added to 100 10f P815/CD28" cells (2.5 x 10° cells/test) in incubation tubes (Skatron Macrowell Tube Strips, catalog # 15773, Molecular Devices, Sunnyvale, CA), and incubated for 90 minutes at 4 C with gentle shaking.
Isotype control antibodies HUEP5C7 and MuFd79 (400 g/ml) in 50 1of BB were also tested as nonspecific competitors. Following the incubation, the cell-antibody mixture was transferred to centrifuge tubes (Sarstedt
Micro Tubes, catalog # 72.702, Sarstedt, Newton, NC) containing 0.1 ml 80% dibutyl phthalate-20% olive oil, the incubation tubes were washed once with 50 1 of BB, and bound and free counts were separated by centrifugation as described (Kuziel, W.A., S.J. Morgan, T.C. Dawson, S. Griffin, 0. Smithies, K. Ley, N.
Maeda. 1997. Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc. Natl. Acad. Sci. 94:12053-12058). This experiment was repeated three times.
Results
The relative binding affinities of the MuTN228 and HuTN228 antibodies were compared in an '*’]- labeled antibody competition experiment as described in the Method. A representative result is shown in
Figure 13. Both MuTN228 and HuTN228 competed with 125] labeled MuTN228 in a concentration dependent manner. The isotype control antibody MuFd79 showed weak but repeatable competition at high concentrations, but the isotype control antibody HUuEPSC7 did not compete with I-labeled MuTN228, indicating that the
HuTN228 antibody recognizes the CD28 antigen through V-region specific interactions. The ICs, values of
®
MuTN228 and HuTN228 for all three experiments are shown in Table 3. The apparent binding affinity of
HuTN228 was approximately 2.4 fold less than that of the MuTN228 antibody.
Table 3. 1-125 competition summary
ICso (nM) cl i LN J
Example 15 Amino acid sequencing of the hamster anti-murine CD28 antibody
Method
Hybridoma and antibodies. The Armenian hamster anti-murine CD28 hybridoma PV1 was obtained from
ATCC (ATCC HB-12352). Purified PV1, R-phycoerythrin (R-PE)-conjugated PV1 were purchased from
Southern Biotechnology (Birmingham, AL). The Syrian hamster anti-CD28 antibody 37.51 was from
PharMingen (San Diego, CA). Secondary antibodies fluorescein (FITC)-conjugated donkey anti-Armenian hamster IgG (H+L), FITC-conjugated donkey anti-Syrian hamster IgG (H+L), FITC-conjugated donkey anti- mouse IgG (H+L), R-PE-F(ab’)2 donkey anti-mouse IgG (H+L) were from Jackson ImmunoResearch (West
Grove, PA); and FITC-conjugated goat anti-mouse kappa, R-PE-conjugated goat anti-mouse 1gG3, and horse radish peroxidase (HRP)-conjugated goat anti-mouse kappa were from Southern Biotechnology. Goat anti- mouse IgG3, and mouse IgG3 isotype control FLOPC 22 were from Sigma Chemicals (St. Louis, MO). The
Armenian hamster anti-murine CD3 antibody 145.2C11 and its hamster/mouse chimeric version 145.2C11-IgG3 were generated in our laboratory. FITC-conjugated 145.2C11 was from Boehringer Mannheim (Indianapolis,
IN).
Cloning of variable region cDNAs. The V region cDNAs for the light and heavy chains of PV1 were cloned from the hybridoma cells by an anchored polymerase chain reaction (PCR) method described by Co et al. (Co,
M.S., N.M. Avadalovic, P.C. Caron, M.V. Avadalovic, D.A. Scheinberg, and C. Queen. 1992. J. Immunol. 148:1149-1154.). Amplification was performed on cDNA using 3' primers that anneal respectively to the hamster kappa and gamma chain C regions, and a 5' primer that anneals to the added G-tail of the cDNA. For
PCT/US01/47955 @, PCR, the 3° primer has the sequence of 5’ TATAGAGCTCCACTTCCAGTGCCC (SEQ ID NO::21), with residues 11- 24 hybridizing to the hamster Cy region. For Vy PCR, the 3’ primers has the degenerated sequences of (SEQ ID NOS:'18, 19 and 20): a GT 5 TATAGAGCTCAAGCTTCCAGTGCATAGACCGATEGGECTIGTCGTTTTGGC, } T with residues 19 - 50 hybridizing to most rodent IgG Cyl. The non-hybridizing sequences in the two primer sets contain restriction sites used for cloning. The V| and Vy cDNAs were subcloned into a pUC19 vector for sequence determination. To avoid PCR-generated errors, five independent clones for each cDNA were sequenced, and only the clones whose sequence agreed with the consensus sequence were chosen to express the chimeric PV1.
Results :
Cloning of PV] V region cDNAs. The PV1 light and heavy chain V region cDNAs were cloned from the hybridoma cells as described in Methods. For the Vi PCR, only 3° primer corresponding to the hamster Gy region could yield Vi cDNA product from PV1. A 3’ primer from the hamster C, region, on the other hand, did not yield any PCR product. These results indicated that the hybridoma PV1 uses kappa for its light chain.
Several light and heavy chain clones were sequenced and were found to contain the same V; and Vy, respectively. Limited Cyl and Cy Sequence data indicated that the cloned heavy and light chains are not murine in origin.
Example 16 Construction and expression of chimeric PV1-1gG3.
Method
PV1 V, and Vy were made by PCR into mini-exon segments flanked by Xbal sites as described (He, X.Y., Z.
Xu, J. Melrose, A. Mullowney, M. Vasquez, C. Queen, V. Vexler, C. Klingbeil, M.S. Co, and E.L. Berg. 1998.
J. Immunol. 160:1029-1035.) and they were separately introduced to the light chain and heavy chain expression plasmids (Fig. 14). Each mini-exon contains a signal peptide sequence, a mature variable region sequence and a 5” splicing donor sequence derived from the most homologous mouse J chain gene. Such splicing donor is used to splice the V region exon to the mouse antibody constant region. Each mini-exon was sequenced again after it
AMENDED SHEET
@ had been cloned into the expression vector to ensure the correct splicing signal was introduced, and no PCR errors were generated.
A vector was constructed to express both the heavy and light chain genes of the chimeric PV1-1gG3 from a single plasmid. In this report, PV1-IgG3 refers to a chimeric antibody containing the hamster PV1 V, and Vy variable regions, a mouse IgG3 constant region for the heavy chain, and a mouse kappa constant region for the light chain. The expression vector pV1.g3.rg.dE (Fig. 14) was obtained by a two-step cloning process similar to that described by Cole et. al. (Cole, M.S., C. Anasetti, and J.Y. Tso. 1997. J. Immunol. 159:3613- 3621.). The heavy chain constant region was derived from the mouse y3 genomic fragment, and the light chain from the k fragment. Both the heavy and light chain genes are driven by the human cytomegalovirus major immediate early promoter and enhancer, and they are separated by the transcription terminator derived from the human complement gene C2 (Ashfield, R., P. Enriquez-Harris, and N.J. Proudfoot. 1991. EMBO J. 10:4197- 4207.). The selection marker gpt gene (Mulligan, R.C., and P. Berg. 1981. Proc. Natl. Acad. Sci. USA 78:2072- 2076) is driven by a modified SV40 early promoter. For expression of the chimeric PV1-IgG3, the single plasmid vector was transfected into the murine myeloma cell line NSO, and the transfectants were selected for gpt expression. Spent media from transfectants were analyzed for mouse IgG3 antibody production by ELISA, using goat anti-mouse IgG3 as capturing reagent and HRP-conjugated goat anti-mouse kappa chain as developing reagent. The assay is specific for mouse IgG3; other mouse IgG isotypes are negative in this analysis.
Results
Expression of the chimeric PV1-1gG3. The cloned Vi and Vy were made into mini-exons (Fig. 15) and incorporated into an expression vector as described in Materials and Methods and Fig. 15. The expression vector was then transfected into a murine myeloma cell line NSO to produce the chimeric PV1-IgG3. Spent media from several transfectants were assayed by ELISA for the production of mouse IgG3 antibodies and by
FACScan for binding to EL4 cells. Most transfectants were positive in both assays. One transfectant was chosen for its high antibody productivity and expanded to grow in 1 L of serum-free medium. PV1-IgG3 was purified from the 1 L spent medium by affinity chromatography. The yield was >10 mg/L.
®
Example 17 Characterization of the purified chimeric PVI-IgG3 by HPLC and SDS-PAGE
Methods | ’
Protein Purification. One of the high IgG3-expressing transfectants (Clone #1) was grown in 1 L of Gibco
Serum-free Hybridoma medium. Spent culture supernatant was harvested when cell viability reached 30 % or below, concentrated to 200 ml, and loaded onto a 5 ml protein-A Sepharose column using a Pharmacia P1 pump (2-3 ml/min). The column was then washed with PBS containing an additional 0.1 M NaCl (final concentration of NaCl was 0.25 M) before the antibody was eluted with 3.5 M MgCl. The eluted protein was then desalted onto a PD10 column equilibrated with PBS containing an additional 0.1 M NaCl. The desalted protein solution was filtered through a 0.2 pm filter prior to storage at 4 °C. Like all mouse IgG3, PV1-IgG3 at high concentrations (>1 mg/mL) precipitates in the cold but returns to solution by warming at 37° C. The antibody stays in solution at room temperature. Repeated cycles of cold precipitation do not seem to affect the antigen binding activity of the antibody.
Purity Determination by size exclusion HPLC and SDS-PAGE. Size exclusion HPLC was performed using a
Perkin Elmer HPLC system consisting of a PE ISS 200 Advanced LC Sample Processor, a PE Series 410 Bio
LC Pump, a PE 235C Diode Array Detector, and a PE Nelson 600 Series LINK. Perkin Elmer Turbochrom
Navigator Version 4.1 software was used to control the autosampler, pump, and detector, and to acquire, store, and process the data. Separation was achieved using two TosoHaas TSK-GEL G3000SWXL size exclusion
HPLC columns (TosoHaas, catalog # 08541, 7.8 mm x 300 mm, 5 pm particle size, 250 A pore size) connected in series. The mobile phase was 200 mM potassium phosphate/1 50 mM potassium chloride at pH 6.9, and the flow rate was 1.00 mL/minute. The column eluate was monitored spectrophotometrically at both 220 nm and 280 nm. The injection volume was 50 uL (63.5 ug) of the undiluted PV1-IgG3 sample. SDS-PAGE was performed according to standard procedures.
Results : . The purity of the isolated PV1-IgG3 was analyzed by size exclusion HPLC and SDS-PAGE. The HPLC elution profile of PV1-IgG3 is shown in Fig. 16. Based on this analysis, the protein is 99% monomer and has the mobility corresponding to the molecular weight of 150 kD. SDS-PAGE analysis of PV1, PV1-IgG3 and isotype control under nonreducing conditions also indicated all three antibodies have the molecular weight of about 150 kD (Fig. 17A). The minor bands seen in Fig. 17A were artifacts due to boiling of the samples in SDS without reduction. They reflected the number of incomplete inter-chain disulfide bonds in the antibodies.
Analysis of the same three proteins under reducing conditions (Fig. 17B), however, indicated that PV, but not
PV1-1gG3 or the isotype control, has a heavy chain with molecular weight slightly higher than the 50 kD molecular weight usually seen with IgG. The hamster antibody PV1 thus either has heavy glycosylation at
Asnpg7 in Cy3, or it has an extra glycosylation site elsewhere in the heavy chain. As discussed later, this unusual glycosylation pattern may contribute to PV1’s nonspecific binding to EL4 cells, perhaps by lectin/carbohydrate interaction.
Example 18
Methods
Flow cytometry. Murine T cell line EL4 cells (2.5 x 10° cells/0.2 ml) were stained with 1 pg/ml of PV1, 37.51 or PVI-IgG3 at 4° C for 30 min, washed with 2 ml of cold PBS, and stained with 20 pl of specific fluorochrome- conjugated secondary antibodies (10 pg/ml). After 20 min of incubation at 4° C in the dark, the cells were washed with PBS and analyzed by FACScan (Becton Dickenson, Milpitas, CA).
In the competition experiment, EL4 cells 2.5% 10° cells/0.2 ml) were stained with 1 pg/ml of R-PE-PV1 and 25 pg/ml of PV1, PV1-IgG3, or IgG3 isotype control at 4° C for 30 min in the dark, washed with PBS and analyzed by FACScan. Similar competition experiment was also conducted using various versions of 145.2C11.
In the reverse competition experiment, EL4 cells (2.5 x 10° cells/0.2 ml) were stained with 1 pg/ml of PV1- . IgG3 and 25 pg/ml of PV1 at 4° C for 30 min, washed 2 times with PBS, stained with FITC-conjugated donkey anti-mouse IgG (H+L), washed, and analyzed by FACScan. To control for nonspecific binding of the secondary antibodies to PV1, EL4 cells were stained with excess PV1 without PV1-IgG3 and analyzed.
For mouse T cell staining, BALB/c mouse splenic cells (2.5 x 10° cells/0.2 ml) were stained with 1 pg/ml of mouse 1gG3 isotype control (FLOPC 21) or PVI-IgG3 at 4° C for 30 min, washed with 2 ml of cold PBS, and stained with 20 pul of FITC-conjugated 145.2C11 (10 pg/ml) and 20 pl of R-PE-conjugated goat anti-mouse
@
IgG3 (10 pg/ml). After 20 min of incubation at 4° C in the dark, the cells were washed with PBS and analyzed by FACScan.
Results
Characterization of PV1 and PV1-IgG3 by flow cytometry. PV1 was used to stain CD28-positive T cell line
EL4 and analyzed by FACScan. The pattern of staining indicated that PV1 binds EL4 cells at two different sites (Fig. 17A). In addition, PV1 as well as several Armenian hamster anti-murine T cell antibodies (145.2C11, anti-CD3; H57-597, anti-TCR; and UC10-4F10-11, anti-CTLA4) also bind nonspecifically to CD28-negative myeloma cell line NSO (data not shown). The Syrian hamster anti-CD28 antibody 37.51, on the other hand, binds specifically to only one site on EL4 cells (Fig. 17B). It appears that, in addition to CD28 binding, PV1 also binds nonspecifically to other sites, possibly through the carbohydrate/lectin type of interaction. As shown in Fig. 17C, the chimeric PV1-IgG3 does not contain this nonspecific binding activity. The antibody binds EL4 cells in a pattern similar to that of 37.51, and it does not bind to CD28-negative NSO cells (data not shown).
Thus, the nonspecific binding property of PV1 lies in the heavy chain constant region of this particular antibody and it is eliminated upon chimerization.
To demonstrate that PV1-IgG3 contains the CD28-specific binding activity, we used the FACScan competition assay. In these experiments, R-PE-conjugated PV1 was mixed with excess (25-fold) unlabeled PV1, PV1-IgG3 or mouse IgG3 control, and the mixture was used to stain EL4 cells. As shown in Fig. 18A, both PV1 and PV1-
IgG3, but not isotype control, prevented R-PE-conjugated PV1 from binding to EL4 cells. The inhibition by
PV1-IgG3 was less than that by PV1, and we interpreted these data as PV1-IgG3 competed with R-PE- "conjugated PV1 for the CD28 sites but not for the nonspecific sites. Similarly, both 145.2C11(Armenian hamster anti-murine CD3) and the chimeric 145.2C11-IgG3 prevented R-PE-conjugated 145.2C11 from binding to EL4 cells (Fig. 18B), but the chimeric antibody is less efficient due to its inability to eliminate R-PE- 145.2C11°s nonspecific binding to cells.
We also did the reverse competition experiment using excess (25-fold) PV1 to compete with PV1-IgG3 for binding to EL4 cells. Although PV-1-IgG3 was not labeled in this case, it was specifically recognized by the
FITC-conjugated donkey anti-mouse antibodies. The results in Fig. 18C showed that the inhibition of PV1-
@®
IgG3’s binding to EL4 cells by excess PV1 was almost complete, demonstrating that PV1 and PV1-IgG3 bind to the same epitope.
Finally, PV1-IgG3 was used to stain mouse splenic cells. PV1-IgG3-coated splenic cells were specifically recognized by the secondary antibodies R-PE-conjugated goat anti-mouse IgG3. Simultaneously, FITC- conjugated 145.2C11 was also added to splenic cells to label CD3-positive cells. In the two-color flow cytometry analysis. PV1-IgG3 specifically stained CD3-positive cells, but not CD3-negative cells (Fig. 19B).
Mouse IgG3 isotype control, on the other hand, did not stain the CD3-positive cells (Fig. 19A). Thus, the chimeric PV1-IgG3 recognizes an antigen that is expressed on murine T cells, an antigen binding activity that is consistent with an anti-CD28 antibody.
Example 19 Induction of Collagen Induced Arthritis
Methods
Mice were immunized intradermally at the base of the tail with 125 pg of bovine CII (Collagen Gijutsu
Kenkyukai, Japan) emulsified with an equal volume of CFA (Wako, Japan). Mice were boosted by intradermal injection with 125ug of bovine CII in CFA on day 21. Mice were treated anti-CD28 antibody (PV1-IgG3) at the dose of mg/kg/day continuous infusion via osmotic pump for 7days after the initial immunization. Arthritis development was checked by inspection of four paws on day 11 after the second immunization, and the inflammation of four paws was graded from 0 to 3 as described previously (Tada, Y., A. Ho, D.-R. Koh, T. W.
Mak. 1996. J. Immunol. 156:4520, . Tada, Y., A. Ho, T. Matsuyama, T. W. Mak. 1997. J. Exp. Med. 185:231).
Each paw was graded and the four scores were added such that the maximal score per mouse was 12. The - arthritis index was calculated by dividing the total score of the experimental mice by the number of the total number of mice. :
Results
®
Mice were immunized with bovine CII, and observed for development of arthritis. At day 11 after the second immunization, arthritis index was significantly reduced in mice treated with anti-CD28 antibody (0.63 %0.50) (P<0.01) versus control (7.50£0.66). ’
Example 20
Methods
Mice;Animals
Female BALB/c and C3H mice were obtained from Charles River Japan, Inc. (Yokohama, Japan). Animals were all housed in a specific pathogen-free facility in microisolator cages with filtered air and free access to food and water. All mice were 6-8 wk of age when experiments were initiated.
Antibodies;
Anti-mouse silent CD28 (PV 1-IgG3) has identical specificity to that of PV-1 clone but it docs not have strong agonistic activity in vitro (Fc—IgG3). Anti-mouse CD154 (TRAP1, IgGl) was purchased from BD PharMingen (San Diego, CA). CTLA4-Ig (CTLA-4/Fc Chimera) was purchased from Genzyme (Cambridge, MA).
Tail-Skin transplantation;
Full thickness skin grafts (0.5 cm2) from tail of donor mice(BALB/c:H-2d) were transplanted on the dorsal thorax of recipient mice(C3H:H-2b) and secured with a band-aid for 7 days. Graft survival was then followed by daily visual inspection. Rejection was defined as the >80% loss of viable epidermal graft tissue. Statistical analyses were performed using a Dunnett’s Multiple Comparison test. Values of p < 0.05 were considered significant.
Treatment protocols;
Skin graft recipients were treated with 10, 50, 250 pg of anti-mouse silent CD28, 250 pg of anti-mouse CD154 and 100 pg of CTLA4-Ig administered i.p. on the day of transplantation (day 0) and on postoperative days 3, and 6.
®
Results;
Simultaneous blockade of the CD40 and CD28 T cell costimulatory pathways by administration of anti-mouse silent CD28 and anti-mouse CD 154 effectively promotes skin allograft survival in C3H mice. Control animals rejected their grafts at 9 days. Anti-CD40L mAb alone modestly prolonged allograft survival (MST 10 days), but was seen to dramatically improve survival when combined with CD28 extending median survival time- (MST-) beyond 33 days. This strategy is markedly less effective in administration of CTLA4-Ig and anti-mouse
CD40L mAb, with MST of 12 days.
Example 21 Preparation of Fab and F(ab”)2 fragment and of anti-CD28 antibody
Preparation of Fab fragment of anti-CD28 antibody
Anti-human CD28 antibody (HuTN228) was digested with immobilized-Ficin (Pierce, USA). Immobilized ficin was activated with S0mM Tris-HCL pH 6.8 buffer containing SmM EDTA and 11.5mM cysteine HCI and packed to a column. Antibody solution was added to the column, and incubated at 37°C for 2 or 3 days. The column was washed with PBS and the digest was concentrated by ultrafiltration. The concentrated digest was applied to the gel-filtration column (TSKgel-3000SWxl, Tosoh, Japan) and appropriate fractions were collected and concentrated by ultrafiltration. Protein concentration was determined by absorbance at 280nm (Abs280 = 1.4 for Img/mL) and the fragment size was confirmed by SDS-PAGE.
Preparation of F(ab")2 fragment of anti-CD28 antibody
Anti-human CD28 antibody was prepared with the same method as that of Fab fragment except for the concentration of cysteine (1.15mM) and the period of incubation (one over night).
Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.
All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.
Claims (43)
1. A silenced anti-CD28 antibody.
2. The antibody of Claim 1 which is a chimeric antibody.
3. The antibody of Claim I which is a humanized antibody.
} 4. The antibody of Claim 1 which has a variable region comprising the amino acid sequence in SEQ ID NO:2 or SEQ ID NO:4.
5. The antibody of Claim 1 which has a variable region comprising the amino acid sequence in SEQ ID NO:2 and SEQ ID NO:4.
6. The antibody of Claim 1 which has a variable region comprising the amino acid sequence in SEQ ID NO:7 or SEQ ID NO:9.
© 7. The antibody of Claim 1 which has a variable region comprising the amino acid sequence in SEQ ID NO:(7 and SEQ ID NO:9. '
8. A polynucleotide encoding the antibody of Claim 1.
9. The polynucleotide of Claim 8 which comprises at least one polynucleotide selected from the group consisting of SEQ ID NO:1, SEQ ID NO:13, SEQ ID NO:6, and SEQ ID NO:8.
10. An expression vector comprising the polynucleotide of Claim 8.
11. A host cell comprising the polynucleotide of Claim 8.
12. A host cell comprising the expression vector of Claim 10.
13. A method of producing a silenced anti-CD28 antibody comprising AMENDED SHEET
@o PCT/US01/47955 culturing the host cell of Claim 11 under conditions suitable for expression of the antibody and recovering the expressed antibody from said culture.
14. A method of producing a silenced anti-CD28 antibody comprising culturing the host cell of Claim 12 under conditions suitable for expression of the antibody and recovering the expressed antibody from said culture.
15. A method of producing a silenced anti-CD28 antibody comprising introducing the polynucleotide of Claim 8 into a host cell; culturing the host cell under conditions suitable for expression of the antibody; and recovering the expressed antibody from said culture.
16. The method of Claim 15 wherein said polynucleotide comprises at least one polynucleotide selected from the group consisting of SEQ ID. NO:1, SEQ ID NO: 3, SEQ ID NO: 6, and SEQ ID NO: 8.
17. A method of producing a silcenced anti-CD28 antibody comprising introducing the expression vector of Claim 10 into a host cell; culturing the host cell under conditions suitable for expression of the antibody; and recovering the expressed antibody from said culture.
18. A pharmaceutical composition comprising the silenced anti-CD28 antibody of Claim 1 and a pharmaceutically acceptable ingredient.
19. A method of inducing T-cell tolerance in a subject comprising administering an effective amount of the antibody of Claim 1 to induce T-cell tolerance to said subject.
20. The method of Claim 19, wherein said administering further comprises administering another immunosuppressant.
21. Use of the antibody of Claim 1 in the manufacture .of a preparation for providing immunosuppression in a patient. 34 AMENDED SHEET
> ay PCT/US01/47955
22. Use of Claim 21, wherein said preparation is administrable with another immunosuppressant.
23. Use of the antibody of claim 1, in the manufacture of a preparation for treating organ or tissue transplant rejection in a patient.
24. Use of Claim 23, wherein said preparation is administrable with another immunosuppressant.
25. An antibody HuTN228.
26. Use of the antibody of Claim 1, in the manufacture of a preparation for inducing T-cell tolerance in a subject.
27. Use of Claim 26, wherein said preparation is administrable with another immunosuppressant.
28. A substance or composition for use in a method of inducing T-cell tolerance in a subject, said substance or composition comprising the antibody of Claim 1, and said method comprising administering an effective amount of said substance or composition to said subject.
29. A substance or composition for use in a method of treatment of Claim 28, wherein said administering further comprises administering another immunosuppressant.
30. A substance or composition for use in a method of providing immunosuppression in a patient, said substance or composition comprising the antibody of Claim 1, and said method comprising administering an effective amount of said substance or composition to said patient.
31. A substance or composition for use in a method of treatment of Claim 30, wherein said administering further comprises administering another immunosuppressant. AMENDED SHEET
Q PCT/US01/47955
32. A substance or composition for use in a method of treating organ or tissue transplant rejection in a patient, said substance or composition comprising the antibody of claim 1, and said method comprising administering an effective amount of said substance or composition to said patient.
33. A substance or composition for use in a method of treatment of Claim 32, wherein said administering further comprises administering another immunosuppressant.
34. An antibody according to Claim 1, or Claim 25, substantially as herein described and illustrated.
35. A polynucleotide according to Claim 8, substantially as herein described and illustrated.
36. A vector according to Claim 10, substantially as herein described and illustrated.
37. A host cell according to Claim 11, or Claim 12, substantially as herein described and illustrated.
38. A method according to any one of Claims 13 to 15, or 17, substantially as herein described and illustrated.
39. A composition according to Claim 18, substantially as herein described and illustrated.
40. A method according to Claim 19, substantially as herein described and illustrated.
41. Use according to any one of Claims 21, or 23, or 26, substantially as herein described and illustrated.
42. A substance or composition for use in a method of treatment according to any one of claims 28, or 30, or 32, substantially as herein described and illustrated.
43. A new antibody, a new polynucleotide, a new vector, a new host cell, a new method of producing an antibody, a new composition, a new non-therapeutic method of treatment, a new use of the antibody of Claim 1, or a substance or composition for a new use in a method of treatment, substantially as herein described. 36 AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25515500P | 2000-12-14 | 2000-12-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200305384B true ZA200305384B (en) | 2004-10-11 |
Family
ID=22967074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200305384A ZA200305384B (en) | 2000-12-14 | 2003-07-11 | Silenced anti-CD28 antibodies and use thereof. |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1341553A4 (en) |
JP (1) | JP2004515243A (en) |
KR (1) | KR20040020866A (en) |
CN (1) | CN1272345C (en) |
AR (1) | AR031924A1 (en) |
AU (2) | AU2002226086C1 (en) |
BR (1) | BR0116686A (en) |
CA (1) | CA2432736A1 (en) |
CZ (1) | CZ20031909A3 (en) |
HU (1) | HUP0400697A3 (en) |
IL (1) | IL156262A0 (en) |
MX (1) | MXPA03005327A (en) |
NO (1) | NO20032542L (en) |
NZ (1) | NZ526569A (en) |
PL (1) | PL363239A1 (en) |
RU (1) | RU2261723C2 (en) |
WO (1) | WO2002047721A1 (en) |
ZA (1) | ZA200305384B (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080095774A1 (en) * | 2001-02-16 | 2008-04-24 | Wyeth | Agents and Methods for Specifically Blocking CD28-Mediated Signaling |
US7531168B2 (en) | 2001-02-16 | 2009-05-12 | Genetics Institute Llc | Method for downmodulating immune response in type I diabetes |
EP3673919A1 (en) | 2005-06-14 | 2020-07-01 | Amgen Inc. | Self-buffering protein formulations |
FR2951176A1 (en) | 2009-10-09 | 2011-04-15 | Tcl Pharma | MONOVALENT LIGANDS OF THE HUMAN CD28 RECEPTOR |
EP2536764B1 (en) * | 2010-02-18 | 2018-07-04 | OSE Immunotherapeutics | Anti-cd28 humanized antibodies |
JP6884858B2 (en) | 2016-10-21 | 2021-06-09 | アムジエン・インコーポレーテツド | Pharmaceutical product and its manufacturing method |
US20210251994A1 (en) | 2018-06-15 | 2021-08-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
CN113692286A (en) * | 2019-03-14 | 2021-11-23 | 比昂生物制剂公司 | A method for immunosuppression |
EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
EP4172323A1 (en) | 2020-06-29 | 2023-05-03 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
IL300666A (en) | 2020-08-19 | 2023-04-01 | Xencor Inc | Anti-cd28 compositions |
US20220325287A1 (en) | 2021-03-31 | 2022-10-13 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
AU2022303363A1 (en) | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521288A (en) * | 1990-03-26 | 1996-05-28 | Bristol-Myers Squibb Company | CD28IG fusion protein |
-
2001
- 2001-12-14 EP EP01995504A patent/EP1341553A4/en not_active Withdrawn
- 2001-12-14 WO PCT/US2001/047955 patent/WO2002047721A1/en not_active Application Discontinuation
- 2001-12-14 AR ARP010105828A patent/AR031924A1/en unknown
- 2001-12-14 AU AU2002226086A patent/AU2002226086C1/en not_active Ceased
- 2001-12-14 NZ NZ526569A patent/NZ526569A/en unknown
- 2001-12-14 IL IL15626201A patent/IL156262A0/en unknown
- 2001-12-14 RU RU2003121231/15A patent/RU2261723C2/en not_active IP Right Cessation
- 2001-12-14 JP JP2002549291A patent/JP2004515243A/en not_active Withdrawn
- 2001-12-14 CZ CZ20031909A patent/CZ20031909A3/en unknown
- 2001-12-14 PL PL01363239A patent/PL363239A1/en not_active Application Discontinuation
- 2001-12-14 HU HU0400697A patent/HUP0400697A3/en unknown
- 2001-12-14 BR BR0116686-7A patent/BR0116686A/en not_active IP Right Cessation
- 2001-12-14 MX MXPA03005327A patent/MXPA03005327A/en unknown
- 2001-12-14 AU AU2608602A patent/AU2608602A/en active Pending
- 2001-12-14 KR KR10-2003-7007798A patent/KR20040020866A/en not_active Application Discontinuation
- 2001-12-14 CN CNB018226361A patent/CN1272345C/en not_active Expired - Fee Related
- 2001-12-14 CA CA002432736A patent/CA2432736A1/en not_active Abandoned
-
2003
- 2003-06-05 NO NO20032542A patent/NO20032542L/en not_active Application Discontinuation
- 2003-07-11 ZA ZA200305384A patent/ZA200305384B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1341553A4 (en) | 2004-07-28 |
JP2004515243A (en) | 2004-05-27 |
BR0116686A (en) | 2003-12-30 |
AU2002226086C1 (en) | 2006-03-09 |
RU2261723C2 (en) | 2005-10-10 |
AU2002226086B2 (en) | 2005-08-25 |
AR031924A1 (en) | 2003-10-08 |
RU2003121231A (en) | 2005-02-10 |
CZ20031909A3 (en) | 2003-11-12 |
NZ526569A (en) | 2005-07-29 |
NO20032542L (en) | 2003-08-07 |
KR20040020866A (en) | 2004-03-09 |
PL363239A1 (en) | 2004-11-15 |
CA2432736A1 (en) | 2002-06-20 |
WO2002047721A1 (en) | 2002-06-20 |
HUP0400697A2 (en) | 2004-06-28 |
MXPA03005327A (en) | 2004-12-03 |
IL156262A0 (en) | 2004-01-04 |
HUP0400697A3 (en) | 2007-05-02 |
CN1489473A (en) | 2004-04-14 |
AU2608602A (en) | 2002-06-24 |
NO20032542D0 (en) | 2003-06-05 |
EP1341553A1 (en) | 2003-09-10 |
CN1272345C (en) | 2006-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2244720C2 (en) | Antibody igg with affinity binding with respect to antigenic complex cd3, recombinant nucleic acids encoding antibody light and heavy chain, method for preparing system, method for preparing antibody, method for treatment of patient | |
EP0966485B1 (en) | MUTATED NONACTIVATING IgG2 DOMAINS AND ANTI-CD3 ANTIBODIES INCORPORATING THE SAME | |
KR100191152B1 (en) | Cd4 specific recombinant antibody | |
AU751064B2 (en) | Antibodies against human CD40 | |
US6887673B2 (en) | Humanized antibodies against human 4-1BB | |
CA2212750C (en) | Humanized antibodies against cd3 | |
JP4804357B2 (en) | Modified anti-CD52 antibody | |
RU2630656C2 (en) | ANTIBODIES AGAINST αβTCR | |
AU2002226086B2 (en) | Silensed anti-CD28 antibodies and use thereof | |
KR20050111748A (en) | Humanized anti-cd4 antibody with immunosuppressive properties | |
EP2583980A1 (en) | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates | |
US5951983A (en) | Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies | |
JP4448906B2 (en) | CD4-specific antibody TRX1 and uses thereof | |
AU754185B2 (en) | LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation | |
TW201726716A (en) | Antibody-cytokine engrafted compositions and methods of use for immunoregulation | |
KR20070036138A (en) | Optimized dosing with anti-cd4 antibodies for tolerance induction in primates | |
AU2002226086A1 (en) | Silensed anti-CD28 antibodies and use thereof | |
MXPA01008098A (en) | Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith. | |
CN102369219A (en) | Antibodies against human tweak and uses thereof | |
US20040116675A1 (en) | Silenced anti-cd28 antibodies and use thereof | |
GB2376467A (en) | TRX1 Antibodies | |
JP7278623B2 (en) | ANTI-CD27 ANTIBODY AND USES THEREOF |